期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 17, 页码 -出版社
MDPI
DOI: 10.3390/ijms23179981
关键词
ovarian cancer; protease; nanomedicine; nanoparticle; matrix metalloproteinase; cathepsin; trypsin; urokinase plasminogen activator; kallikrein
资金
- Burroughs Wellcome Fund Physician Scientist Institutional Award
- Houston Methodist Cancer Center
- Department of Defense/US Army Medical Research [W81XWH2110012]
This review provides an overview of the clinical features and diagnostic importance of ovarian cancer, focusing on the role of proteases in its progression and the potential of protease-enabled nanomedicines for diagnosis and therapy.
Ovarian cancer (OvCa) is one of the leading causes of mortality globally with an overall 5-year survival of 47%. The predominant subtype of OvCa is epithelial carcinoma, which can be highly aggressive. This review launches with a summary of the clinical features of OvCa, including staging and current techniques for diagnosis and therapy. Further, the important role of proteases in OvCa progression and dissemination is described. Proteases contribute to tumor angiogenesis, remodeling of extracellular matrix, migration and invasion, major processes in OvCa pathology. Multiple proteases, such as metalloproteinases, trypsin, cathepsin and others, are overexpressed in the tumor tissue. Presence of these catabolic enzymes in OvCa tissue can be exploited for improving early diagnosis and therapeutic options in advanced cases. Nanomedicine, being on the interface of molecular and cellular scales, can be designed to be activated by proteases in the OvCa microenvironment. Various types of protease-enabled nanomedicines are described and the studies that focus on their diagnostic, therapeutic and theranostic potential are reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据